Alnylam Pharmaceuticals Inc ALNY
$280.16▼ -2.26% 24H
Super Investor & Insider
1
Fondi che lo detengono
#730
Rank consenso
1.4%
% dei portafogli
$638.3M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Dodge & Cox · Dodge & Cox | 0.35% | Reduce 1.79% | 1,929,253 | $638.3M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing RNA interference (RNAi) therapeutics. This innovative gene silencing technology targets the root causes of diseases at the genetic level, offering potential treatments for rare and prevalent conditions across multiple t…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees2,500
TickerALNY
Statistics
Market Cap$37.39B
Revenue (TTM)$3.71B
Net Income$313.7M
Net Margin8.4%
EPS$3.99
P/E74.61
P/S9.27
P/B36.94
EV/EBITDA49.21
ROE90.4%
Dividend Yield—
Price$280.16
Data: Twelve Data · Revenue = mcap / P/S